MDCO News and Press, The Medicines Company From 10/01/19

The Medicines Company (NASDAQ: MDCO) is up 161% this year, thanks in large part to the success of its cholesterol-lowering drug inclisiran. In August, the company announced that one of its late-stage clinical trials, Orion-11, was positive, which was followed by a presentation a few days ...

The Medicines Company (NASDAQ: MDCO ) announces positive results from two Phase 3 clinical trials for inclisiran. Both studies met all primary and secondary endpoints with no new safety signals reported. Detailed data will be presented at the American Heart Association Scientific Sessions in...

­ ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ­ ORION-10 completion marks successful conclusion of pivotal Phase 3 LDL-C lowering studies of in...

­ ORION-9 study met all primary and secondary efficacy endpoints ­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe ­ Detailed data from ORION-9 will be presented in a late-breaki...

Cellular Biomedicine Group (NASDAQ: CBMG ) initiated with Buy rating and $19 (28% upside) price target at BTIG Research. More news on: Cellular Biomedicine Group, Inc., Lexaria Bioscience Corp., Orchard Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...

After the Federal Trade Commission (FTC) demanded Bristol-Myers Squibb (NYSE: BMY) sell its blockbuster Otezla to secure approval for its $74 billion acquisition of Celgene (NASDAQ: CELG) , a bidding war resulted in Amgen (NASDAQ: AMGN) agreeing to pay $13.4 billion in cash for the ps...

Concerns about the effect of the trade war on the economy deepened Tuesday after new tariffs went in place over the weekend and a report showed that U.S. factory activity in August contracted for the first time in three years. The  Dow Jones Industrial Average (DJINDICES: ^DJI)  ...

Shares of The Medicines Company (NASDAQ: MDCO) , a biopharmaceutical company focused on lowering cholesterol, are on the move again following yesterday's presentation of the Orion-11 trial results. Healthcare-minded investors pleased with the details drove the stock 10.4% higher on Tuesday....

Tuesday was a bad day on Wall Street, as investors reacted negatively to new tariffs that went into effect between the U.S. and China. Many market participants had hoped that the two parties would agree to some kind of temporary reprieve to avoid the uptick in trade tensions, but it now appears ...

When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock. Solid Boost The Medicines Company (NASDAQ:MDCO) an...